Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.51 |
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6050865 | 0.73 | MAPT (0.38) | POLBMEN1KMT2AKDM4EELANE | |
| SCHEMBL16670318 | 0.72 | POLB (0.55) | CA1CA2POLBMEN1KMT2A | |
| SCHEMBL4261482 | 0.69 | CA1 (1.00) | CA1CA2MEN1KMT2AKDM4E | |
| SCHEMBL16670248 | 0.69 | POLB (0.52) | CA1CA2POLBMEN1KMT2A | |
| SCHEMBL3675405 | 0.67 | CA1 (0.54) | CA1CA2POLBMEN1KMT2A | |
| SCHEMBL6366697 | 0.66 | POLB (0.52) | CA1CA2POLBMEN1KMT2A | |
| SCHEMBL15953118 | 0.66 | POLB (0.55) | CA1CA2POLBMEN1KMT2A | |
| SCHEMBL8945552 | 0.65 | NQO1 (0.58) | MEN1KMT2AKDM4EELANEALDH1A1 | |
| SCHEMBL28906179 | 0.64 | MAPT (0.45) | CA1CA2MEN1KMT2AKDM4E | |
| SCHEMBL29940494 | 0.64 | MAPT (0.45) | CA1CA2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176254-A1 | DNA PK INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-20090042865-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| WO-2009010761-A1 | DNA PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042865-A1 | DNA-PK INHIBITORS | DNA2, PKN2, TOP1 | CA1 4158/4885CA2 3327/4885POLB 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.